Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros,  Tricia L Thomas, L Jay KatzFrom the Glaucoma Service Department of Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAAbstract: Glaucoma is a chronic progressive optic neuropathy characterized...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9b1703a1ec80495eac0001d11f943bb1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros,  Tricia L Thomas, L Jay KatzFrom the Glaucoma Service Department of Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAAbstract: Glaucoma is a chronic progressive optic neuropathy characterized by progressive loss of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal rim tissue, defects in the retinal nerve fiber layer, and deficits on functional visual field testing. The goal of glaucoma treatment is to reduce the intraocular pressure to a level that prevents or minimizes the progressive loss of vision. The current standard of management for the newly diagnosed primary open angle glaucoma (PAOG) patient is to start topical medication. Available topical medications include: beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydraze inhibitors, prostaglandin analogues and miotics. In some patients, IOP is not adequately controlled by monotherapy. In those refractory patients, where more efficacy is required, shifting to another medication or adding a second medication is indicated. The complimentary action between two drugs serves as the basis for combination medications. One avenue of delivering a second medication is through a fixed combination medication that has the advantage of providing two medicines within one drop. Bimatoprost/timolol represents a new fixed combination which is clinically and statistically more effective than either of its active constituents for patients with refractory glaucoma. As regard the safety of the combination, there were no signs or symptoms of intolerance and the incidence of conjunctival hyperemia was clinically and statistically significantly less than each of the two components separately. Bimatoprost/timolol fixed combination offers cost and time savings, which may enhance compliance; also reducing the amount of preservative applied to the eye, will improve tolerability and may also favorably improve eventual surgical outcomes in patients who might require filtering procedures.Keywords: fixed combination, refractory glaucoma, timolol/bimatoprost |
|---|